GoAI
Get started
Hansoh Pharmaceutical Group Company Limited logo

Hansoh Pharmaceutical Group Company Limited

3692.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$31.24

−HK$1.84 · -5.56%

Aug 24, 3:07 PM HKT

3692.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Hui Juan Zhong
Listed since
Jun 14, 2019
Employees
9,347

Market position

Day range

Current HK$31.24

52-week range

Current HK$31.24

Open
HK$33.30
Previous close
HK$33.08
Volume
13.87M
1.22× average
Average volume
11.34M
Average daily volume
Market cap
189.41B HKD
Beta
0.56
Market reference 1
50-day average
HK$31.8876
-2.03% below average
200-day average
HK$35.7165
-12.53% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
190.49B CNY
P/E (TTM)
28.82×
P/B (TTM)
4.55×
P/S (TTM)
10.81×
EV / EBITDA
33.04×
Earnings yield
2.87%
Free cash flow yield
3.22%
Dividend yield
1.38%

Profitability & efficiency

Gross margin
89.89%
Operating margin
36.04%
Net margin
36.97%
Return on equity
15.70%
Return on assets
13.92%
Return on invested capital
12.91%

Financial health

Debt / equity
0×
Current ratio
8.09×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends98%72%46%21%Gross margin, FY2021: 91.24%Gross margin, FY2022: 90.73%Gross margin, FY2023: 89.80%Gross margin, FY2024: 90.98%Gross margin, FY2025: 89.89%Operating margin, FY2021: 29.15%Operating margin, FY2022: 28.47%Operating margin, FY2023: 28.10%Operating margin, FY2024: 32.88%Operating margin, FY2025: 36.04%Net margin, FY2021: 27.31%Net margin, FY2022: 27.54%Net margin, FY2023: 32.44%Net margin, FY2024: 35.66%Net margin, FY2025: 36.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 91.24%. Gross margin FY2022 90.73%. Gross margin FY2023 89.80%. Gross margin FY2024 90.98%. Gross margin FY2025 89.89%. Operating margin FY2021 29.15%. Operating margin FY2022 28.47%. Operating margin FY2023 28.10%. Operating margin FY2024 32.88%. Operating margin FY2025 36.04%. Net margin FY2021 27.31%. Net margin FY2022 27.54%. Net margin FY2023 32.44%. Net margin FY2024 35.66%. Net margin FY2025 36.97%.

Income trends

Revenue

15.03B CNY+22.57%

Operating income

5.42B CNY+34.34%

Net income

5.56B CNY+27.07%
Income trends across reported periods16.27B CNY11.29B CNY6.32B CNY1.34B CNYRevenue, FY2021: 9.94B CNYRevenue, FY2022: 9.38B CNYRevenue, FY2023: 10.1B CNYRevenue, FY2024: 12.26B CNYRevenue, FY2025: 15.03B CNYOperating income, FY2021: 2.9B CNYOperating income, FY2022: 2.67B CNYOperating income, FY2023: 2.84B CNYOperating income, FY2024: 4.03B CNYOperating income, FY2025: 5.42B CNYNet income, FY2021: 2.71B CNYNet income, FY2022: 2.58B CNYNet income, FY2023: 3.28B CNYNet income, FY2024: 4.37B CNYNet income, FY2025: 5.56B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.94B CNY. Revenue FY2022 9.38B CNY. Revenue FY2023 10.1B CNY. Revenue FY2024 12.26B CNY. Revenue FY2025 15.03B CNY. Operating income FY2021 2.9B CNY. Operating income FY2022 2.67B CNY. Operating income FY2023 2.84B CNY. Operating income FY2024 4.03B CNY. Operating income FY2025 5.42B CNY. Net income FY2021 2.71B CNY. Net income FY2022 2.58B CNY. Net income FY2023 3.28B CNY. Net income FY2024 4.37B CNY. Net income FY2025 5.56B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue15.03B CNY12.26B CNY10.1B CNY9.38B CNY9.94B CNY
Cost of goods sold1.52B CNY1.11B CNY1.03B CNY870.19M CNY870.39M CNY
Gross profit13.51B CNY11.16B CNY9.07B CNY8.51B CNY9.06B CNY
Research and development3.36B CNY2.7B CNY2.1B CNY1.69B CNY1.8B CNY
Selling, general, and administrative4.74B CNY4.51B CNY4.24B CNY4.15B CNY4.37B CNY
Operating expenses8.09B CNY7.12B CNY6.23B CNY5.84B CNY6.17B CNY
Interest income1.08B CNY995.26M CNY905.01M CNY309.09M CNY164.09M CNY
Interest expense3.16M CNY6.69M CNY66.68M CNY58.14M CNY52.82M CNY
Depreciation and amortization364.36M CNY375.57M CNY366.38M CNY324.37M CNY278.47M CNY
Operating income5.42B CNY4.03B CNY2.84B CNY2.67B CNY2.9B CNY
Net income5.56B CNY4.37B CNY3.28B CNY2.58B CNY2.71B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+11.23%
11 comparable reports
Latest EPS result
0.45
Estimate 0.38 · Beat by 17.65%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.620.480.340.2Q1 '23BeatQ3 '23MissQ1 '24BeatQ3 '24BeatQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26Estimate
Q1 2023, reported Mar 27, 2023: actual 0.247, estimate 0.24, surprise +2.75%, Beat. Q3 2023, reported Aug 31, 2023: actual 0.235, estimate 0.249, surprise -5.67%, Miss. Q1 2024, reported Mar 26, 2024: actual 0.361, estimate 0.242, surprise +49.21%, Beat. Q3 2024, reported Aug 27, 2024: actual 0.493, estimate 0.418, surprise +17.95%, Beat. Q1 2025, reported Mar 24, 2025: actual 0.298, estimate 0.245, surprise +21.72%, Beat. Q3 2025, reported Aug 18, 2025: actual 0.577, estimate 0.392, surprise +47.12%, Beat. Q1 2026, reported Mar 29, 2026: actual 0.448, estimate 0.381, surprise +17.65%, Beat. Q3 2026, reported Aug 26, 2026: actual —, estimate 0.565, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.9B8.1B6.3B4.5BQ1 '23MissQ3 '23MissQ1 '24BeatQ3 '24BeatQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26Estimate
Q1 2023, reported Mar 27, 2023: actual 5.64B HKD, estimate 6.29B HKD, surprise -10.46%, Miss. Q3 2023, reported Aug 31, 2023: actual 4.88B HKD, estimate 5B HKD, surprise -2.40%, Miss. Q1 2024, reported Mar 26, 2024: actual 6.19B HKD, estimate 6.09B HKD, surprise +1.71%, Beat. Q3 2024, reported Aug 27, 2024: actual 6.99B HKD, estimate 6.69B HKD, surprise +4.44%, Beat. Q1 2025, reported Mar 24, 2025: actual 6.12B HKD, estimate 5.89B HKD, surprise +4.00%, Beat. Q3 2025, reported Aug 18, 2025: actual 8.13B HKD, estimate 7.15B HKD, surprise +13.72%, Beat. Q1 2026, reported Mar 29, 2026: actual 8.5B HKD, estimate 8.18B HKD, surprise +3.95%, Beat. Q3 2026, reported Aug 26, 2026: actual —, estimate 9.52B HKD, surprise —, Comparison unavailable.

3692.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

—

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.80

—

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

—

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.56

—

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.40

—

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. logo

6990.HK

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

HK$520

—

Continue in GoAI

Research 3692.HK

research.disclaimer